Sponsored by Thermo Fisher Scientific
Leveraging Infectious Disease Diagnostics Developments Post-Pandemic
The COVID-19 pandemic underscored the importance of molecular diagnostics and compelled laboratories to quickly validate new methods and increase testing capacity through the expansion of resources and high-throughput automation. As SARS-CoV-2 infections reach an equilibrium, and the virus moves from a pandemic to an endemic disease, testing demand is decreasing, revealing the opportunity to address broader public health needs through the expansion of infectious disease diagnostics.
Aegis BioPharma Laboratory launched COVID-19 testing in April 2020 with a daily capacity of 3,000 tests and quickly scaled during that first year to over 100,000 tests per day. The lab has performed over 14.2 million COVID-19 PCR tests to date, servicing a broad network across the United States, Puerto Rico, and the US Virgin Islands. Aegis leveraged the partnerships, technologies, and infrastructure developed during the COVID-19 surge to build the infectious disease testing menu aimed at limiting the spread of health risks within the community.
Attendees of this webinar will learn how Aegis is:
- Utilizing extra resources and capacity to create opportunities for business development and laboratory growth, post-pandemic.
- Standardizing laboratory processes and procedures to efficiently add new workflows.
- Creating flexible and customizable infectious disease panels that provide actionable results to meet the ever-changing public health needs.